Legal Uncertainties and Patent Fight Could Be a Game Changer for Pfizer (PFE) [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
of generic drug price-fixing, and also faced a key patent claim construction ruling in an ongoing lawsuit concerning its COVID-19 vaccine lipid nanoparticle technology. These legal events could affect both Pfizer's financial obligations and the ongoing exclusivity of its vaccine technology, raising uncertainty around future costs and operational outcomes for the company. We'll look at how this increased legal exposure shapes Pfizer's investment narrative, especially given ongoing litigation over its vaccine patents. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. Pfizer Investment Narrative Recap For shareholders, the key case for Pfizer centers on its ability to offset looming patent expirations and regulatory risks by delivering new product launches and pipeline growth. This month's US$70.75 million generic price-fixing settlement and a pivotal patent ruling for i
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Olema Oncology to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 12/1/25 - Form 4
- 11/25/25 - Form 4
- 11/19/25 - Form 8-K
- OLMA's page on the SEC website